Consequently, in patients with clinical suspicion of SMA with 1 copy of SMN1 after a quantitative molecular test, sequencing of the whole coding region of the SMN1/2 genes is warranted to look for the possible pathogenic SNV. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.